Novo Nordisk Unveils Promising Weight Loss Results from Amycretin Clinical Trial

Novo Nordisk has announced promising results from its phase 1b/2a clinical trial of amycretin, a novel once-weekly subcutaneous treatment for individuals with overweight or obesity. Amycretin is a unimolecular GLP-1 and amylin receptor agonist designed to aid weight loss.

The trial assessed the safety, tolerability, pharmacokinetics, and efficacy of amycretin in 125 participants. The primary endpoint focused on treatment-emergent adverse events, which were consistent with those observed in incretin-based therapies. The most common side effects were gastrointestinal, predominantly mild to moderate in severity.

Participants began with an average body weight of 92.7 kg. Those treated with amycretin experienced significant weight reductions:

• 1.25 mg dose (20 weeks): 9.7% weight loss

• 5 mg dose (28 weeks): 16.2% weight loss

• 20 mg dose (36 weeks): 22.0% weight loss

  
  

In contrast, placebo recipients saw weight gains of 1.9%, 2.3%, and 2.0% over the same periods.

Martin Lange, Novo Nordisk's executive vice president for Development, expressed optimism: "We are very encouraged by the subcutaneous phase 1b/2a results for amycretin in people living with overweight or obesity. The results seen in the trial support the weight-lowering potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, that we have previously seen with the oral formulation."

Building on these findings, Novo Nordisk plans to advance amycretin's clinical development for adults with overweight or obesity.

Amycretin represents a new class of treatment, combining GLP-1 and amylin receptor agonism, and is being developed for both oral and subcutaneous administration.

Novo Nordisk, founded in 1923 and headquartered in Denmark, is a global healthcare leader aiming to combat serious chronic diseases. The company employs approximately 72,000 people across 80 countries and markets its products in around 170 countries.